Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 0.69 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.69 |
| ▸ | GRAMD1A | Q96CP6 | 6/20 | 0.61 |
| ▸ | STAT3 | P40763 | 3/20 | 0.56 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | WEE1 | P30291 | 2/20 | 0.51 |
| ▸ | PLK1 | P53350 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24418645 | 0.98 | CRBN (0.69) | CRBNDDB1GRAMD1ASTAT3MAP1LC3B | |
| SCHEMBL29558320 | 0.98 | CRBN (0.69) | CRBNDDB1GRAMD1ASTAT3MAP1LC3B | |
| SCHEMBL24620900 | 0.95 | DDB1 (0.71) | CRBNDDB1GRAMD1ASTAT3MAP1LC3B | |
| SCHEMBL25360001 | 0.94 | CRBN (0.62) | CRBNDDB1GRAMD1ASTAT3MAP1LC3B | |
| SCHEMBL30526088 | 0.94 | CRBN (0.62) | CRBNDDB1GRAMD1ASTAT3MAP1LC3B | |
| SCHEMBL21107253 | 0.93 | CRBN (0.68) | CRBNDDB1GRAMD1ASTAT3MAP1LC3B | |
| SCHEMBL21855437 | 0.93 | CRBN (0.67) | CRBNDDB1GRAMD1ASTAT3MAP1LC3B | |
| SCHEMBL23343290 | 0.91 | CRBN (0.67) | CRBNDDB1GRAMD1ASTAT3HDAC3 | |
| SCHEMBL23568544 | 0.89 | CRBN (0.70) | CRBNDDB1GRAMD1ASTAT3HDAC3 | |
| SCHEMBL30772320 | 0.89 | CRBN (0.70) | CRBNDDB1GRAMD1ASTAT3MAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230010508-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-01-12 | — | — | US | disclosed |
| EP-4107152-A1 | BCL-2 PROTEIN INHIBITORS | Recurium IP Holdings, LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| CN-115461335-A | BCL-2 protein inhibitors | 里科瑞尔姆IP控股有限责任公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021086069-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | 재단법인 대구경북첨단의료산업진흥재단 | 2021-05-06 | — | — | WO | disclosed |
| EP-3728251-A1 | BIFUNCTIONAL INHIBITORS WITH EGFR HAVING A E3 UBIQUITIN LIGASE MOIETY | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200308171-A1 | BIFUNCTIONAL INHIBITORS WITH EGFR HAVING A E3 UBIQUITIN LIGASE MOIETY | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200308171-A1 | BIFUNCTIONAL INHIBITORS WITH EGFR HAVING A E3 UBIQUITIN LIGASE MOIETY | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308171-A1 | BIFUNCTIONAL INHIBITORS WITH EGFR HAVING A E3 UBIQUITIN LIGASE MOIETY | EGFR, ERBB2, MDM2 | CRBN 250/4885DDB1 324/4885GRAMD1A 1225/4885 |
| US-20230010508-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | EZH2, BMI1, SUZ12 | CRBN 53/4885DDB1 440/4885GRAMD1A 3606/4885 |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | CRBN 325/4885DDB1 181/4885GRAMD1A 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.